Bristol-Myers Squibb Earnings Reinforces Our Thesis
Bristol-Myers Squibb Company stock crossed $50/share after strong earnings. The company saw 18% YoY revenue growth in 2Q 2024. Bristol-Myers has a strong pipeline with potential for future growth, ...
6 Blue Chip Dividend Stock Bargains to Buy Now That All Yield 5% and More
24/7 Wall St. Insights Dividend stocks will outperform when the Federal Reserve starts to lower rates in September.
Bristol Myers Squibb Shows Resilience Amid Patent Expiry Challenges (Rating Upgrade)
Bristol Myers Squibb's Q2 2024 revenue increased 9% year-over-year, reaching $12.2 billion. Newer drugs like Reblozyl and Opdualag demonstrated strong revenue growth in Q2, 2024. Despite facing pat...
2 High-Yield Dividend Stocks That Could Shine in 2025
Dividend yields have historically been a strong predictor of stock returns over long periods. Current market conditions could be ripe for a rally in high-yield equities.
Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point
Bristol-Myers Squibb had a strong Q2 earnings report, backed by strong momentum in both legacy and new products. The management has boosted its guidance for the remainder of 2024, enhancing confide...
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.
Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug Sales
Bristol-Myers Squibb (BMY) shares climbed Friday after the company beat expectations with its second-quarter results and raised its full-year guidance.
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $1.64 per share. This compares to earnings of $1.75 per share a year ago.
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
Bristol Myers Squibb reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance. Revenue growth was primarily driven by the company's blockbuster blood ...
3 Defensive Stocks to Shield Your Portfolio in July
Defensive stocks are stealing the spotlight again following Fed Chair Jerome Powell's recent comments. In his address at the Economic Club of Washington D.C.
Bristol Myers Squibb: The More It Drops, The More I Buy
Stock market investing is not a zero-sum game, offering long-term potential for growth and income when it comes to highly undervalued stocks. Bristol Myers Squibb stock is undervalued, with strong ...
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
Bristol Myers faces multiple challenges, but if it can overcome them, its stock could prove to be a steal of a deal. Cisco's sales haven't gotten a boost yet from AI, but it may only be a matter of...
2 Pharma Stocks to Buy Hand Over Fist This Month
Pfizer and Bristol Myers have faced issues recently that have led to poor stock market performances. However, both drugmakers are spinning their innovative wheels and look likely to bounce back.
5 Under $50 Dividend Stocks to Buy Now
24/7 Insights Dividend stocks offer investors the opportunity to increase investment total return.
3 High-Yield S&P 500 Dividend Stocks That You Can Buy With $100 Right Now
Bristol Myers Squibb upset investors with a big acquisition-related expense, but its pharmaceutical business is stronger than ever. Vici Properties is a real estate investment trust that collects r...
Related Companies